中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2011年
7期
726-727
,共2页
心房颤动%稳心颗粒%胺碘酮
心房顫動%穩心顆粒%胺碘酮
심방전동%은심과립%알전동
Atrial fibrillation%Wenxin granules%Amiodarone
目的 观察稳心颗粒联合胺碘酮转复及预防心房颤动复发的疗效.方法 选择慢性心房颤动患者共60例,随机分为稳心颗粒联合胺碘酮组(A组)及单纯胺碘酮组(B组)各30例,所有患者入院后静脉应用胺碘酮24 h同时口服胺碘酮由600 mg/d逐渐减量至200 mg/d维持,另外A组同时给予口服步长稳心颗粒(9 g,3次/d)共4周.观察2组患者4周内转复窦性心律情况及半年内复发情况.结果 第2、3、4周内累积转复窦性心律例数A组显著高于B组(分别是73.3%与43.3%,x2=5.55:83.3%与63.3%,x2=3.07;90.0%与66.7%,x2=4.81;P均<0.05),半年内复发B组有高于A组的趋势.结论 稳心颗粒联合应用胺碘酮转复心房颤动疗效优于单纯应用胺碘酮,并且半年内复发率可能更低.
目的 觀察穩心顆粒聯閤胺碘酮轉複及預防心房顫動複髮的療效.方法 選擇慢性心房顫動患者共60例,隨機分為穩心顆粒聯閤胺碘酮組(A組)及單純胺碘酮組(B組)各30例,所有患者入院後靜脈應用胺碘酮24 h同時口服胺碘酮由600 mg/d逐漸減量至200 mg/d維持,另外A組同時給予口服步長穩心顆粒(9 g,3次/d)共4週.觀察2組患者4週內轉複竇性心律情況及半年內複髮情況.結果 第2、3、4週內纍積轉複竇性心律例數A組顯著高于B組(分彆是73.3%與43.3%,x2=5.55:83.3%與63.3%,x2=3.07;90.0%與66.7%,x2=4.81;P均<0.05),半年內複髮B組有高于A組的趨勢.結論 穩心顆粒聯閤應用胺碘酮轉複心房顫動療效優于單純應用胺碘酮,併且半年內複髮率可能更低.
목적 관찰은심과립연합알전동전복급예방심방전동복발적료효.방법 선택만성심방전동환자공60례,수궤분위은심과립연합알전동조(A조)급단순알전동조(B조)각30례,소유환자입원후정맥응용알전동24 h동시구복알전동유600 mg/d축점감량지200 mg/d유지,령외A조동시급여구복보장은심과립(9 g,3차/d)공4주.관찰2조환자4주내전복두성심률정황급반년내복발정황.결과 제2、3、4주내루적전복두성심률례수A조현저고우B조(분별시73.3%여43.3%,x2=5.55:83.3%여63.3%,x2=3.07;90.0%여66.7%,x2=4.81;P균<0.05),반년내복발B조유고우A조적추세.결론 은심과립연합응용알전동전복심방전동료효우우단순응용알전동,병차반년내복발솔가능경저.
Objective To observe the treatment effect and relapse prevention of cardioversion of atrial fibrillation with Wenxin granules and amiodarone. Methods Sixty patients of chronic atrial fibrillation were divided randomly into treatment of Wenxin granules and amiodarone group (group A) and treatment of simple amiodarone gorup(group B),Thirty cases in each group. All cases were treated with amiodarone by intravenous drip along with oral amiodarone. Thirty cases in group A were treated with Wenxin granules (9 grams,per day) additionally for 4 weeks. Results Patients in group A resumed normal sinus rhythm significantly higher than that in group B. The increasing relapse tendency of atrial fibrillation was higher in group B within 6 months. Conclusion Drug combination with Wenxin granules and amiodarone has better effect than simple amiodarone in the relapse prevention of cardioversion of atrial fibrillation.